040sek
-1,5 %
Date:2025-06-26Time:16:48:50Latest report:Q1-2025List:SpotlightTicker:PHAL
Market Cap:21 msekEnterprise Value:24 msekNet Sales:- msekEarnings:-4,08 msekEmployees:0ISIN:SE0003359710

Ratios

10-year key figure history for PharmaLundensis turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for PharmaLundensis with index and moving average MA50 and MA200.

Stockprice:0,40
MA50:0,53
MA200:0,64
Price/MA200:-37,5 %
RSI (14):47,6
Price/MA50:-25,1 %

Description

PharmaLundensis is a research company. Main focus is on the treatment of severe pulmonary diseases. The three diseases the company is specialised in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition, development is made on system that eliminates the release of pharmaceutical pollution. PharmaLundensis is based in Lund.

Biotechnology